Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1845544 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HCAR3MITFLMNAMAPT | |
| SCHEMBL1845392 | 0.87 | LMNA (0.35) | ALDH1A1LMNAMAPTRAB9AL3MBTL1 | |
| SCHEMBL1845394 | 0.87 | LMNA (0.35) | ALDH1A1LMNAMAPTRAB9AL3MBTL1 | |
| SCHEMBL1846707 | 0.85 | ALDH1A1 (0.37) | ALDH1A1MITFLMNAMAPTL3MBTL1 | |
| SCHEMBL1846705 | 0.85 | ALDH1A1 (0.37) | ALDH1A1MITFLMNAMAPTL3MBTL1 | |
| SCHEMBL4311290 | 0.73 | TSHR (0.43) | ALDH1A1MITFLMNAMAPTRAB9A | |
| SCHEMBL16737121 | 0.72 | GPR35 (0.36) | ALDH1A1MITFLMNAMAPTESR2 | |
| SCHEMBL1845001 | 0.71 | PTPRF (0.46) | ALDH1A1LMNAMAPT | |
| SCHEMBL27735366 | 0.70 | CA1 (0.40) | ALDH1A1LMNAMAPTESR2RAB9A | |
| SCHEMBL11185663 | 0.69 | LMNA (0.40) | ALDH1A1HCAR3LMNAMAPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102149703-B | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | LAILA NUTRACEUTICALS | 2014-09-10 | — | — | CN | claimed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | claimed |
| CN-102149703-A | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | LAILA NUTRACEUTICALS | 2011-08-10 | — | — | CN | claimed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | claimed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | claimed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | claimed |
| CN-102149703-B | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | LAILA NUTRACEUTICALS | 2014-09-10 | — | — | CN | disclosed |
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | disclosed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| CN-102149703-A | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | LAILA NUTRACEUTICALS | 2011-08-10 | — | — | CN | disclosed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | BRAF, NRAS, TP53 | ALDH1A1 731/4885HCAR3 2834/4885MITF 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.